Biotechnology News and Research

RSS

Study lays groundwork to develop new treatments for cardiovascular disease and other conditions

In a significant step toward restoring healthy blood circulation to treat a variety of diseases, a team of scientists at Weill Cornell Medical College has developed a new technique and described a novel mechanism for turning human embryonic and pluripotent stem cells into plentiful, functional endothelial cells, which are critical to the formation of blood vessels.

21 Jan 2010

New effort to produce standardized DNA parts for reducing development time of synthetic biology in labs

With seed money from the National Science Foundation (NSF), bioengineers from the University of California, Berkeley, and Stanford University are ramping up efforts to characterize the thousands of control elements critical to the engineering of microbes so that eventually, researchers can mix and match these "DNA parts" in synthetic organisms to produce new drugs, fuels or chemicals.

21 Jan 2010

Global health community to be engaged in using resources of GSK and Alnylam IP Pool

BIO Ventures for Global Health, GlaxoSmithKline (GSK), and Alnylam announced today that the organizations are partnering to engage the global health community in using the powerful resources of the GSK and Alnylam Intellectual Property (IP) Pool.

21 Jan 2010

Quorum sensing offers a dynamic approach to increase sensitivity to external signals

Researchers at UC San Diego who last year genetically engineered bacteria to keep track of time by turning on and off fluorescent proteins within their cells have taken another step toward the construction of a programmable genetic sensor. The scientists recently synchronized these bacterial "genetic clocks" to blink in unison and engineered the bacterial genes to alter their blinking rates when environmental conditions change.

21 Jan 2010

Simulations Plus board authorizes renewed share repurchase program

Simulations Plus, Inc., the leading provider of simulation and modeling software for pharmaceutical discovery and development, announced today that its board of directors has authorized a renewed share repurchase program effective Monday, February 15, 2010.

21 Jan 2010

6th Annual Diabetes Conference to feature ocular drug delivery in diabetic retinopathy

pSivida Corp., a leader in the development of tiny, sustained-release drug delivery technologies, with two of the only three ophthalmic sustained-release delivery products approved by the FDA for treatment of back of the eye diseases, announced that its chief executive officer, Dr. Paul Ashton, will discuss ocular drug delivery in diabetic retinopathy during a presentation at the 6th Annual Diabetes Conference in London, on Friday, January 22.

21 Jan 2010

BARDA awards Duke University $3.7M to develop diagnostic test for detecting radiation exposure

Duke University has received a $3.7 million contract from the Biomedical Advanced Research and Development Authority (BARDA) to develop a rapid and accurate genomic-based diagnostic test that can determine if a person has been exposed to radiation from a dirty bomb or nuclear attack. In the event that all option years are exercised by the government, Duke University could receive up to $43.6 million from the contract.

21 Jan 2010

NHC urges congress to continue work on meaningful healthcare reform

The National Health Council (NHC), an organization providing a united voice for the more than 133 million people with chronic diseases and disabilities and their family caregivers, today sent a letter to Congress urging the House and Senate to "continue working to accomplish the long-sought goal of health care reform."

21 Jan 2010

New class of HCV inhibitors discovered by Eiger BioPharmaceuticals

Eiger BioPharmaceuticals, Inc., a biotechnology company developing antiviral therapies, announced today the publication of research from the labs of Stanford scientist and Eiger Founder, Dr. Jeffrey Glenn, M.D., Ph.D. and colleagues entitled, "Identification of a Novel Class of HCV Inhibitors". Published in the January 20th edition of Science and Translational Medicine, the research validates a domain, termed 4BAH2, within the non-structural protein (NS4B) of the HCV genome, as essential for HCV replication and describes the development of a high-throughput screen leading to the identification of small molecule inhibitors of 4BAH2.

21 Jan 2010

BIO commends GSK and Alnylam’s efforts to foster new therapies for neglected diseases

The Biotechnology Industry Organization (BIO) applauds the joint efforts of BIO members GlaxoSmithKline and Alnylam Pharmaceuticals to encourage research to accelerate medical therapies for neglected diseases and today’s announcement of the selection of BIO Ventures for Global Health (BVGH) as the administrator of the Intellectual Property (IP) Pool.

21 Jan 2010

InterMune prices public offering of newly issued common stock

InterMune, Inc. today announced the pricing of its underwritten public offering of 7,000,000 shares of newly issued common stock at a price to the public of $14.10 per share.

21 Jan 2010

Australia issues patent covering Kane Biotech's DispersinB anti-biofilm technology

Kane Biotech Inc., a biotechnology company engaged in the development of products that prevent and disperse microbial biofilms, is pleased to announce the issuance of Patent No. 2003284385 entitled "Compositions and methods for enzymatic detachment of bacterial and fungal biofilms" by IP Australia (Australian Patent and Trademark Office).

21 Jan 2010

Targeted Genetics receives delisting notification from NASDAQ Stock Market

Targeted Genetics Corporation (the “Company”) today announced that it has received a written notice from the staff of The NASDAQ Stock Market (“NASDAQ”) informing the Company that trading of the Company’s common stock would be suspended prior to the open of business on Thursday, January 21, 2010, and that NASDAQ would initiate procedures to delist the Company’s common stock.

20 Jan 2010

New LNP compositions that improve systemic delivery of RNAi therapeutics discovered

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today announced the publication of new data in the journal Nature Biotechnology by Alnylam scientists and collaborators from Tekmira Pharmaceuticals Corporation, AlCana Technologies, Inc., and The University of British Columbia (UBC). The new study employed a rational design approach for the discovery of novel lipids that can be incorporated into lipid nanoparticles (LNPs) for systemic delivery of RNAi therapeutics.

20 Jan 2010

New white paper examines how PCR mycoplasma tests and analysis save time and money

Contamination by mycoplasmal organisms is an ever-present concern in biopharmaceutical manufacturing. Their properties make them ready sources of contamination, while rendering them difficult and time-consuming to detect. A new free white paper, examines how PCR mycoplasma tests and analysis, deployed by a cutting-edge laboratory, minimizes testing delays and enable safe, high-volume biopharmaceutical production.

20 Jan 2010

AMRI’s Rensselaer labs and manufacturing facilities receive SafeBridge Potent Compound Safety Certification

SAFEBRIDGE® CONSULTANTS, INC., headquartered in Mountain View, California, has announced that AMRI’s high potency research laboratories and GMP-manufacturing facilities in Rensselaer, New York have met the criteria established under the SafeBridge program for “Potent Compound Safety Certification” and have been deemed competent and proficient in the safe handling of potent active pharmaceutical ingredients (“APIs”).

20 Jan 2010

Wound Care Innovations' CellerateRx highlighted at the SuperBones East conference

Wound Management Technologies, Inc., a rapidly growing provider of specialty medical products, announced today that its subsidiary Wound Care Innovations was highlighted as part of a presentation exhibited at the SuperBones East conference in Nassau, Bahamas, on January 14-17. The SuperBones Conference has a great reputation for high quality educational lectures and workshops and places top national speakers at the podium.

20 Jan 2010

Carlos Slim Health Institute launches major research project in genomic medicine

Mexican business leader Carlos Slim Hel- today announced the launch of a major research project in genomic medicine that will help accelerate progress in public health in Mexico and around the world.

20 Jan 2010

Fc engineering enhances antibody half-life

A Nature Biotechnology article published online January 17 reveals that Xencor Inc.’s proprietary Fc engineering extends the half-life of antibodies while maintaining their potency and extending duration of action. These results, published in an article entitled, “Enhanced antibody half-life improves in vivo activity” demonstrate the potential of Fc engineering to impact the flexibility of route, schedule and dose for nearly any antibody.

20 Jan 2010

Fast Forward, JDRF announce collaborative partnership with Axxam SpA

Fast Forward, LLC, the commercial drug development arm of the National Multiple Sclerosis Society, and the Juvenile Diabetes Research Foundation (JDRF), the leader in research leading to a cure for type 1 diabetes in the world today announced a collaborative partnership with Axxam SpA -- a leading company in conducting early-stage discovery research programs for the life science industry -- to develop new treatments for two autoimmune diseases, multiple sclerosis (MS) and type 1 diabetes (T1D).

20 Jan 2010

Biotechnology News and Research

Study lays groundwork to develop new treatments for cardiovascular disease and other conditions

New effort to produce standardized DNA parts for reducing development time of synthetic biology in labs

Global health community to be engaged in using resources of GSK and Alnylam IP Pool

Quorum sensing offers a dynamic approach to increase sensitivity to external signals

Simulations Plus board authorizes renewed share repurchase program

6th Annual Diabetes Conference to feature ocular drug delivery in diabetic retinopathy

BARDA awards Duke University $3.7M to develop diagnostic test for detecting radiation exposure

NHC urges congress to continue work on meaningful healthcare reform

New class of HCV inhibitors discovered by Eiger BioPharmaceuticals

BIO commends GSK and Alnylam’s efforts to foster new therapies for neglected diseases

InterMune prices public offering of newly issued common stock

Australia issues patent covering Kane Biotech's DispersinB anti-biofilm technology

Targeted Genetics receives delisting notification from NASDAQ Stock Market

New LNP compositions that improve systemic delivery of RNAi therapeutics discovered

New white paper examines how PCR mycoplasma tests and analysis save time and money

AMRI’s Rensselaer labs and manufacturing facilities receive SafeBridge Potent Compound Safety Certification

Wound Care Innovations' CellerateRx highlighted at the SuperBones East conference

Carlos Slim Health Institute launches major research project in genomic medicine

Fc engineering enhances antibody half-life

Fast Forward, JDRF announce collaborative partnership with Axxam SpA

Biotechnology eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News